Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 721–780 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…in J; CheckMate 067 Investigators. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1)…
…inc levels also modulate Treg function, and zinc chelation with chloroquine boosts α-PD-1 immunotherapy, highlighting dietary and microbial…
…Background Although immune checkpoint inhibitors (ICIs) have demonstrated success in several solid tumors, response am…
…n solid tumors as evidenced by the approvals of tebentafusp and tarlatamab. Despite these initial clinical successes, there remains a pauc…
…hal form of kidney cancer. Despite therapeutic advances such as VEGF inhibitors, immune checkpoint inhibitors (ICIs) and a recently approved HI…
…y to mediate potent anti-tumor effects when properly activated. Bispecific antibodies that redirect macrophages to recognize and phagocytose cancer c…
…(LICs) showed minimal improvementAbstract 1209 Table 1Impact of Immune Checkpoint Inhibitors on MIR Trends and Equity Gaps by Cancer Type and Income Group. …
… immunotherapies, including novel immune checkpoint inhibitors, bispecific antibodies, immune cell therapies, and advanced manufacturing technologies…
…reased peptide diversity with ASXL1m, even after treatment with IFNγ (p<0.01). Using isogenic K562 HLA-A*02:01 cell lines to control…
…d Galectin-3, CD155, VEGFA, and LAMP1 in CD68 high tumor cells. EGF treatment upregulated CD68 in SNU-423 (3.8-fold at 50 ng/ml; 1.…
…metrics. Organoids were treated with HER2-targeting ADCs (e.g., trastuzumab emtansine), payload-only controls, and isotype antibodies. After 6 days o…
…d-of-care, novel small molecule inhibitors, and next generation antibody-drug conjugates to assess differential drug responses across patient samples.Re…